Career history of Paul Kessler
Former positions of Paul Kessler
| Companies | Position | Start | End |
|---|---|---|---|
Nabi Biopharmaceuticals
 Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Chief Tech/Sci/R&D Officer | 2005-02-28 | 2012-08-04 |
| General Counsel | 2005-02-28 | 2012-08-04 | |
| GENVEC INC | Chief Tech/Sci/R&D Officer | 1997-12-31 | 2004-12-31 |
Training of Paul Kessler
| University of Pittsburgh | Undergraduate Degree |
| University of London | Graduate Degree |
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
Statistics
International
| United States | 5 |
| United Kingdom | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| General Counsel | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
- Stock Market
- Insiders
- Paul Kessler
- Experience
